In summary, our results show the importance of FXN for normal astrocyte function and the therapeutic potential of pharmacologically targeting the SHH signaling pathway on glial cells to attenuate neurodegenerative processes associated with FRDA disease progression. The gene discussed is FXN; the disease is Friedreich ataxia.